GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead™ platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.
Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Title: GalAhead™ Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics
US Media Contact:
Tel: +1 203 939 2225
Asia Media Contact:
Tel: +852 3150 6707
View original content:https://www.prnewswire.com/news-releases/sirnaomics-to-present-latest-developments-on-sirna-therapeutics-for-cancer-and-galaheadtm-platform-programs-at-the-2nd-annual-oligonucleotide-therapeutics-and-delivery-conference-301628476.html
SOURCE Sirnaomics Ltd.